Axcella, a biotechnology company developing medicines for severe conditions caused by disrupted amino acid biology, has added three new members to its senior leadership team: Thomas Leggett, MBA, chief financial officer; Iman Barilero, Pharm.D., Ph.D., senior vice president, chief regulatory science, patient advocacy and pharmacovigilance officer; and Veena Warikoo, Ph.D., vice president, product development.   Mr. Leggett previously spent 13 years as an investment banker at J.P. Morgan Securi...